Differential In Vivo Activities of Anidulafungin, Caspofungin, and Micafungin against Candida glabrata Isolates with and without FKS Resistance Mutations

被引:94
|
作者
Arendrup, Maiken Cavling [1 ]
Perlin, David S. [2 ]
Jensen, Rasmus Hare [1 ]
Howard, Susan Julie [3 ]
Goodwin, Joanne [3 ]
Hope, William [3 ]
机构
[1] Statens Serum Inst, Unit Mycol & Parasitol, DK-2300 Copenhagen, Denmark
[2] UMDNJ New Jersey Med Sch, Publ Hlth Res Inst, Newark, NJ USA
[3] Univ Manchester, Manchester Acad Hlth Sci Ctr, NIHR Translat Res Facil Resp Med, Univ Hosp S Manchester NHS Fdn Trust, Manchester, Lancs, England
基金
美国国家卫生研究院;
关键词
INVASIVE CANDIDIASIS; REDUCED SUSCEPTIBILITY; AMPHOTERICIN-B; ALBICANS; TROPICALIS; ECHINOCANDINS; SUBSTITUTIONS; EPIDEMIOLOGY; ESOPHAGITIS; FLUCONAZOLE;
D O I
10.1128/AAC.06369-11
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
We recently observed that the micafungin MICs for some Candida glabrata fks hot spot mutant isolates are less elevated than those for the other echinocandins, suggesting that the efficacy of micafungin may be differentially dependent on such mutations. Three clinical C. glabrata isolates with or without (S3) fks hot spot mutations R83 (Fks2p-S663F) and RR24 (Fks1p-S629P) and low, medium, and high echinocandin MICs, respectively, were evaluated to assess the in vivo efficacy in an immunocompetent mouse model using three doses of each echinocandin. Drug concentrations were determined in plasma and kidneys by high-performance liquid chromatography (HPLC). A pharmacokinetic-pharmacodynamic mathematical model was used to define the area under the concentration-time curve (AUC) that produced half-and near-maximal activity. Micafungin was equally efficacious against the S3 and R83 isolates. The estimates for the AUCs of each echinocandin that induced half-maximal effect (E(50)s) were 194.2 and 53.99 mg . h/liter, respectively. In contrast, the maximum effect (E-max) for caspofungin was higher against S3 than R83, but the estimates for E-50 were similar (187.1 and 203.5 mg . h/liter, respectively). Anidulafungin failed to induce a >= 1-log reduction for any of the isolates (AUC range, 139 to 557 mg . h/liter). None of the echinocandins were efficacious in mice challenged with the RR24 isolate despite lower virulence (reduced maximal growth, prolonged lag phase, and lower kidney burden). The AUC associated with half-maximal effect was higher than the average human exposure for all drug-dose-bug combinations except micafungin and the R83 isolate. In conclusion, differences in micafungin MICs are associated with differential antifungal activities in the animal model. This study may have implications for clinical practice and echinocandin breakpoint determination, and further studies are warranted.
引用
收藏
页码:2435 / 2442
页数:8
相关论文
共 50 条
  • [21] In vitro interaction of posaconazole and caspofungin against clinical isolates of Candida glabrata
    Oliveira, ER
    Fothergill, AW
    Kirkpatrick, WR
    Coco, BJ
    Patterson, TF
    Redding, SW
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (08) : 3544 - 3545
  • [22] Role of FKS Mutations in Candida glabrata: MIC Values, Echinocandin Resistance, and Multidrug Resistance
    Pham, Cau D.
    Iqbal, Naureen
    Bolden, Carol B.
    Kuykendall, Randall J.
    Harrison, Lee H.
    Farley, Monica M.
    Schaffner, William
    Beldavs, Zintars G.
    Chiller, Tom M.
    Park, Benjamin J.
    Cleveland, Angela A.
    Lockhart, Shawn R.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (08) : 4690 - 4696
  • [23] Paradoxical growth effects of the echinocandins caspofungin and micafungin, but not of anidulafungin, on clinical isolates of Candida albicans and C-dubliniensis
    Fleischhacker, M.
    Radecke, C.
    Schulz, B.
    Ruhnke, M.
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2008, 27 (02) : 127 - 131
  • [24] Paradoxical growth effects of the echinocandins caspofungin and micafungin, but not of anidulafungin, on clinical isolates of Candida albicans and C. dubliniensis
    M. Fleischhacker
    C. Radecke
    B. Schulz
    M. Ruhnke
    European Journal of Clinical Microbiology & Infectious Diseases, 2008, 27 : 127 - 131
  • [25] Killing kinetics of anidulafungin, caspofungin and micafungin against Candida parapsilosis species complex: Evaluation of the fungicidal activity
    Gil-Alonso, Sandra
    Quindos, Guillermo
    Canton, Emilia
    Eraso, Elena
    Jauregizar, Nerea
    REVISTA IBEROAMERICANA DE MICOLOGIA, 2019, 36 (01): : 24 - 29
  • [26] In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin:: Six years of global surveillance
    Pfaller, M. A.
    Boyken, L.
    Hollis, R. J.
    Kroeger, J.
    Messer, S. A.
    Tendolkar, S.
    Diekema, D. J.
    JOURNAL OF CLINICAL MICROBIOLOGY, 2008, 46 (01) : 150 - 156
  • [27] Assessment of caspofungin susceptibility of Candida glabrata by the Etest®, CLSI, and EUCAST methods, and detection of FKS1 and FKS2 mutations
    N. Bourgeois
    C. Laurens
    S. Bertout
    Y. Balard
    D. Krasteva
    P. Rispail
    L. Lachaud
    European Journal of Clinical Microbiology & Infectious Diseases, 2014, 33 : 1247 - 1252
  • [28] Assessment of caspofungin susceptibility of Candida glabrata by the Etest®, CLSI, and EUCAST methods, and detection of FKS1 and FKS2 mutations
    Bourgeois, N.
    Laurens, C.
    Bertout, S.
    Balard, Y.
    Krasteva, D.
    Rispail, P.
    Lachaud, L.
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2014, 33 (07) : 1247 - 1252
  • [29] Comparison of fks gene mutations and minimum inhibitory concentrations for the detection of Candida glabrata resistance to micafungin: A systematic review and meta-analysis
    Bienvenu, Anne-Lise
    Leboucher, Gilles
    Picot, Stephane
    MYCOSES, 2019, 62 (09) : 835 - 846
  • [30] Comparison of the fungicidal activities of caspofungin and amphotericin B against Candida glabrata
    Barchiesi, F
    Spreghini, E
    Tomassetti, S
    Arzeni, D
    Giannini, D
    Scalise, G
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (12) : 4989 - 4992